Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

In­ma­gene Bio­phar­ma­ceu­ti­cals, a biotech de­vel­op­ing im­munol­o­gy treat­ments, will take over the Nas­daq list­ing of Ike­na On­col­o­gy in a re­verse merg­er that ends the tar­get com­pa­ny’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER